Literature DB >> 8771064

Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study.

P Girlanda1, A Quartarone, S Sinicropi, C Nicolosi, C Messina.   

Abstract

We studied six patients affected with blepharospasm (BSP). We injected botulinum toxin (BTX) around only one eye and saline solution around the other. Clinical rating of BSP was performed. Single fiber electromyography (SFEMG), compound motor action potential (cMAP) at the orbicularis oculi muscle by stimulation of the facial nerve, blink reflex, and blink reflex recovery curve were recorded. All clinical and electrophysiological investigations were carried out before, and 1, 2, and 4 weeks after treatment. Evidence of bilateral clinical benefit was provided. Following therapy, facial cMAP decreased bilaterally and SFEMG revealed statistically significant changes on both sides while the excitability curve of blink reflex remained unmodified. The results confirm that BTX affects merely the neuromuscular junctions. The clinical and neurophysiological effects are present on both sides also for unilateral injection probably because of toxin spreading.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8771064     DOI: 10.1002/mds.870110107

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

Review 1.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 2.  Botulinum toxin in the management of blepharospasm: current evidence and recent developments.

Authors:  Amy Hellman; Diego Torres-Russotto
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

3.  Evidence for central antispastic effect of botulinum toxin type A.

Authors:  Ivica Matak
Journal:  Br J Pharmacol       Date:  2019-11-06       Impact factor: 8.739

4.  The role of the trigeminal sensory nuclear complex in the pathophysiology of craniocervical dystonia.

Authors:  Lynley Bradnam; Christine Barry
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

5.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

6.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

7.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

Review 8.  Botulinum Toxin Treatment of Movement Disorders.

Authors:  Yasaman Safarpour; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2018-02-24       Impact factor: 3.598

9.  The blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm.

Authors:  P Schwingenschuh; P Katschnig; M J Edwards; J T H Teo; L V P Korlipara; J C Rothwell; K P Bhatia
Journal:  Neurology       Date:  2011-02-15       Impact factor: 9.910

Review 10.  Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following Injection of Botulinum Toxin-A: A Narrative Review of the Literature.

Authors:  Hélène Moron; Corine Gagnard-Landra; David Guiraud; Arnaud Dupeyron
Journal:  Toxins (Basel)       Date:  2021-05-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.